Solomon Moshkevich Sells 4,692 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 4,692 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $230.76, for a total value of $1,082,725.92. Following the transaction, the insider directly owned 113,065 shares in the company, valued at approximately $26,090,879.40. This trade represents a 3.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total value of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $198.60, for a total transaction of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The stock was sold at an average price of $187.95, for a total value of $54,881.40.
• On Wednesday, October 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $159.99, for a total value of $479,970.00.

Natera Stock Down 0.4%

NASDAQ NTRA traded down $1.00 during trading hours on Tuesday, reaching $227.40. 874,175 shares of the company were exchanged, compared to its average volume of 1,509,833. The stock has a market capitalization of $31.45 billion, a P/E ratio of -99.30 and a beta of 1.63. The business’s 50 day simple moving average is $209.04 and its 200-day simple moving average is $177.74. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $246.90.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period in the previous year, the business earned ($0.26) earnings per share. Natera’s revenue was up 34.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NTRA. Morgan Stanley lifted their price objective on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Piper Sandler upped their price objective on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Wells Fargo & Company raised their target price on shares of Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a report on Monday. Royal Bank Of Canada set a $268.00 target price on shares of Natera and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. increased their price target on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday. Fifteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $229.12.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NTRA. Horizon Investments LLC acquired a new stake in shares of Natera in the third quarter valued at about $32,000. Northwestern Mutual Wealth Management Co. boosted its stake in Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after buying an additional 106 shares during the period. Hilltop National Bank purchased a new stake in Natera in the second quarter valued at approximately $33,000. Oliver Lagore Vanvalin Investment Group acquired a new position in Natera during the 2nd quarter worth about $36,000. Finally, Summit Securities Group LLC purchased a new position in shares of Natera in the first quarter valued at approximately $39,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.